Innovent Biologics: Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...

Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...
The Daily Record (Maryland)

Biologics manufacturing facility to open in Rockville

Samsung Biologics, a biotechnology company based in South Korea, announced plans to open its first U.S. manufacturing facility in Rockville, according to Gov. Wes Moore‘s office. Last month, Samsung ...
Bisnow

Samsung Biologics To Pay $280M For Maryland Manufacturing Campus

South Korean pharmaceutical giant Samsung Biologics is making a major acquisition in the D.C. suburbs to establish its first U.S. manufacturing facility. The company reached an agreement to acquire ...
The Business Journals

Samsung Biologics to acquire GSK's Rockville campus for $280M in first U.S. manufacturing move

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal would give the South ...
Commercial Observer

Samsung Biologics to Acquire First U.S. Drug Manufacturing Facility in $280M Deal

A South Korean biomanufacturing giant is set to purchase its first drug production facility in the U.S. for a sum worthy of its tech giant parent. Samsung Biologics is the world’s largest contract ...
MarketWatch

Samsung Biologics Boosts U.S. Presence With $280M GSK Facility Deal

Samsung Biologics has agreed to buy GSK's Human Genome Sciences for $280 million, expanding the company's footprint into the U.S. market. Samsung Biologics, a biopharmaceutical contract development ...
Reuters

Samsung Biologics to buy US drug production facility from GSK for $280 million

SEOUL, Dec 22 (Reuters) - South Korea's Samsung Biologics (207940.KS), opens new tab said on Monday it is acquiring its first U.S. drug production facility from GSK (GSK.L), opens new tab for $280 ...
Business Facilities

Samsung Biologics Pays $280M For U.S. Drug Manufacturing Facility

M arking a significant expansion of the company’s global footprint and long-term commitment to the U.S. market, Samsung Biologics America (SBA) has entered into an agreement with GSK to acquire 100% ...
Seeking Alpha

The Play On ADMA Biologics: A Discounted Stock With Good Prospects

ADMA Biologics, Inc. projects EPS to quadruple by 2030, supported by strong revenue growth and margin expansion. ADMA's Q3 results exceeded revenue expectations, with adjusted EBITDA up 29% and FY2025 ...
Bloomberg L.P.

Biocon Moves to Fully Own Biologics Unit Valued at $5.5 Billion

Indian pharmaceuticals firm Biocon Ltd. will buy out minority shareholders in Biocon Biologics Ltd. via a mix of cash and shares in a deal that values the biosimilars unit at $5.5 billion. Biocon will ...